Literature DB >> 3028536

Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease.

M E Rick, S B Williams, R A Sacher, L P McKeown.   

Abstract

Thrombocytopenia may accompany variant (type IIB) von Willebrand's disease (vWD) and is thought to result from binding of the abnormal von Willebrand factor (vWF) to the patient's platelets with subsequent platelet aggregate formation and clearance. We have studied a patient with type IIB vWD who became thrombocytopenic during two pregnancies. During the third trimester of pregnancy, her platelet counts dropped to 20,000 to 30,000/microL, and an increase in the intermediate-sized vWF multimers was seen on agarose gel electrophoresis. During this time her platelet-rich plasma showed spontaneous platelet aggregation, and her plasma caused spontaneous aggregation of normal washed platelets. Antibody to platelet glycoprotein Ib completely blocked the spontaneous platelet aggregation, while antibody to platelet glycoprotein IIb/IIIa did not block the response at the concentrations used. Inhibitors of platelet function that elevate platelet cyclic AMP also blocked the response, but aspirin had no effect on the spontaneous platelet aggregation. The patient illustrates that the platelet counts in one individual can vary greatly in type IIB vWD and that the thrombocytopenia that occurs can appear under physiologic conditions that stimulate the endogenous production of the patient's abnormal vWF. The mechanisms leading to spontaneous platelet aggregation and thrombocytopenia appear to be similar to those described for other patients with type IIB vWD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028536

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Thrombocytopenia in pregnancy.

Authors:  S L Janes
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

Review 2.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain.

Authors:  K A Cooney; W C Nichols; M E Bruck; W F Bahou; A D Shapiro; E J Bowie; H R Gralnick; D Ginsburg
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

Review 4.  Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force.

Authors:  I D Walker; J J Walker; B T Colvin; E A Letsky; R Rivers; R Stevens
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

5.  Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.

Authors:  A M Randi; I Rabinowitz; D J Mancuso; P M Mannucci; J E Sadler
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

6.  Von Willebrand Disease and Pregnancy.

Authors:  Muhammad Wasif Saif; Carmen Allegra
Journal:  Consultant       Date:  2001-03

Review 7.  The molecular genetics of von Willebrand disease.

Authors:  Ergül Berber
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831

8.  Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdue.

Authors:  Alessandra Casonato; Viviana Daidone; Eva Galletta; Antonella Bertomoro
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

9.  Management of pregnancy and emergency caesarean delivery in a patient with type IIB von Willebrand disease and severe preeclampsia: A case report and literature review.

Authors:  Daniel Martingano; Xin Guan; Francis X Martingano
Journal:  Obstet Med       Date:  2017-09-13

10.  Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease.

Authors:  Giancarlo Castaman
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-16       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.